Low triiodothyronine syndrome and selenium deficiency - undervalued players in advanced heart failure? A single center pilot study.
Heart failure
Low T3 syndrome
Selenium
Triiodothyronine
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
07 05 2019
07 05 2019
Historique:
received:
27
11
2018
accepted:
11
04
2019
entrez:
9
5
2019
pubmed:
9
5
2019
medline:
28
1
2020
Statut:
epublish
Résumé
The function of deiodinases - selenoproteins converting thyroid hormones may be disturbed by oxidative stress accompanying heart failure. Selenium (Se) may be used by glutathione peroxidase, leading to a lack of deiodinase and triiodothyronine (T3). The aim of the study was the evaluation of the prevalence and clinical significance of low T3 syndrome in heart failure and the assessment of the association of low fT3 and Se deficiency. The study group consisted of 59 consecutive patients hospitalized due to decompensated HFrEF NYHA III or IV. Exclusion criteria were: thyroid dysfunction, severe systemic disease, treatment with amiodarone, steroids or propranolol. Group A included 9 patients with low free T3 (fT3) concentration below 3.1 pmol/L. Group B consisted of the remaining 50 patients with normal fT3 levels. The prevalence of low T3 syndrome was 15.3%. The prevalence of Se deficiency was 74.6%. We demonstrated correlations between fT3 and main clinical variables (i.e. NT-proBNP, LVEF, hsCRP), but we did not find correlation between fT3 and the Se level. Kaplan-Meier survival analysis showed lower survival probability in patients with low fT3 (p < 0.001). Low T3 syndrome is frequently found in patients with HFrEF and is associated with a poor outcome. We did not identify any significant correlation between Se and fT3 level.
Sections du résumé
BACKGROUND
The function of deiodinases - selenoproteins converting thyroid hormones may be disturbed by oxidative stress accompanying heart failure. Selenium (Se) may be used by glutathione peroxidase, leading to a lack of deiodinase and triiodothyronine (T3). The aim of the study was the evaluation of the prevalence and clinical significance of low T3 syndrome in heart failure and the assessment of the association of low fT3 and Se deficiency.
METHODS
The study group consisted of 59 consecutive patients hospitalized due to decompensated HFrEF NYHA III or IV. Exclusion criteria were: thyroid dysfunction, severe systemic disease, treatment with amiodarone, steroids or propranolol. Group A included 9 patients with low free T3 (fT3) concentration below 3.1 pmol/L. Group B consisted of the remaining 50 patients with normal fT3 levels.
RESULTS
The prevalence of low T3 syndrome was 15.3%. The prevalence of Se deficiency was 74.6%. We demonstrated correlations between fT3 and main clinical variables (i.e. NT-proBNP, LVEF, hsCRP), but we did not find correlation between fT3 and the Se level. Kaplan-Meier survival analysis showed lower survival probability in patients with low fT3 (p < 0.001).
CONCLUSIONS
Low T3 syndrome is frequently found in patients with HFrEF and is associated with a poor outcome. We did not identify any significant correlation between Se and fT3 level.
Identifiants
pubmed: 31064347
doi: 10.1186/s12872-019-1076-5
pii: 10.1186/s12872-019-1076-5
pmc: PMC6505272
doi:
Substances chimiques
Biomarkers
0
Triiodothyronine
06LU7C9H1V
Selenium
H6241UJ22B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105Commentaires et corrections
Type : ErratumIn
Références
Eur J Heart Fail. 2005 Jan;7(1):113-8
pubmed: 15642542
ESC Heart Fail. 2015 Mar;2(1):5-11
pubmed: 28834641
Front Horm Res. 2014;43:57-69
pubmed: 24943298
Endocr Rev. 2008 Dec;29(7):898-938
pubmed: 18815314
J Clin Endocrinol Metab. 2008 Apr;93(4):1351-8
pubmed: 18171701
J Card Fail. 2009 Feb;15(1):35-40
pubmed: 19181292
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
J Am Coll Cardiol. 1990 Jul;16(1):91-5
pubmed: 2358611
J Clin Invest. 1986 Apr;77(4):1402-4
pubmed: 3457020
Pol Merkur Lekarski. 2014 Sep;37(219):170-4
pubmed: 25345279
Circulation. 2003 Feb 11;107(5):708-13
pubmed: 12578873
J Cardiol. 2015 Sep;66(3):205-11
pubmed: 25982671
Int J Cardiol. 2017 Jan 1;226:1-10
pubmed: 27776249
J Clin Invest. 2008 Mar;118(3):975-83
pubmed: 18259611
Am J Cardiol. 2014 Mar 1;113(5):845-50
pubmed: 24406111
Heart Fail Rev. 2006 Mar;11(1):13-7
pubmed: 16819573
J Mol Cell Cardiol. 2011 Oct;51(4):506-11
pubmed: 21215270
Anesth Analg. 1997 Oct;85(4):734-8
pubmed: 9322448
Biomed Pharmacother. 2010 Mar;64(3):165-9
pubmed: 19926244
Pol Merkur Lekarski. 2016 Jun;40(240):380-3
pubmed: 27403906
Nat Rev Cardiol. 2017 Jan;14(1):39-55
pubmed: 27811932
Am J Cardiol. 2017 Feb 15;119(4):599-603
pubmed: 28017303
Front Endocrinol (Lausanne). 2012 Jan 26;3:8
pubmed: 22654851
Am J Med. 2005 Feb;118(2):132-6
pubmed: 15694896
Clin Endocrinol (Oxf). 2015 Dec;83(6):931-7
pubmed: 25359424
Eur Heart J. 1996 Dec;17(12):1860-6
pubmed: 8960429
Kardiol Pol. 2018;76(4):713-722
pubmed: 29537483
Am J Cardiol. 1998 Feb 15;81(4):443-7
pubmed: 9485134
Vascul Pharmacol. 2010 Mar-Apr;52(3-4):120-30
pubmed: 19857604
Tex Heart Inst J. 2010;37(5):538-46
pubmed: 20978564
Hormones (Athens). 2011 Apr-Jun;10(2):117-24
pubmed: 21724536
Eur Heart J Cardiovasc Imaging. 2013 Jul;14(7):611-44
pubmed: 23733442